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An interesting aspect of infection with several infectious agents is the possible association
with some diseases apparently not associated with infections. One of the most exciting
examples of this is the association of cardiovascular diseases with infection involving
several different infectious agents. Cytomegalovirus (CMV) is one of the chief candidates
that have been studied. Several epidemiologic reports indicate a possible association of
various forms of vascular disease with the presence and titer of viral antibodies. Other
studies show the presence of virus, viral antigens or nucleic acid in atherosclerotic
lesions. Studies in animal models and cell-culture studies present attractive mechanisms
by which the virus may play a role in the etiology of these diseases. However, negative
results have also been reported, and more research is needed before the ﬁnal verdict on
this exciting question is presented.
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Cardiovascular diseases represent a leading cause
of mortality in industrialized societies. In addition
to known risk factors such as hypertension,
hypercholesterolemia and diabetes mellitus, other
etiologic factors have been suggested. During the
last three or four decades, the possibility of asso-
ciation between various infections and the devel-
opment of atherosclerosis, and particularly
coronary arterial diseases, has been discussed by
many research groups. Several agents have been
studied, most of them viruses, but also Chlamydia
pneumoniae and other bacterial agents. Cytomega-
lovirus (CMV) has been, and still is, one of the
main candidates, and the possible role of this virus
as a cofactor in atherogenesis is discussed in many
reports. The question has been approached from
several viewpoints: seroepidemiologic studies of
groups of patients with and without atherosclero-
tic diseases, detection of the infectious agent, or
parts of it, in the atheromatous lesions, experi-
mental studies in animal models, and in vitro
experimental studies in cell systems with the
aim of looking at possible mechanisms that might
be involved. The clinical deﬁnitions targeted in
various studies are also rather heterogeneous.
They include systemic atherosclerosis, cardiovas-
cular disease, coronary atherosclerosis, coronary
heart disease, carotid, femoral and aortic athero-
sclerosis, coronary artery restenosis after angio-
plasty, graft restenosis in transplanted hearts, and
others.
Several epidemiologic studies have linked ear-
lier CMV infection, indicated by the presence and
quantity of CMV antibodies, to atherosclerosis.
Two-fold or larger odds ratios in relation to
CMV antibodies and cardiovascular disease have
been reported in several epidemiologic studies [1–
8], while others have failed to ﬁnd such an associa-
tion [9–12]. A ﬁnding which strengthens the prob-
ability of association is that of increasing odds
ratios with increasing titers of antibodies and/or
increasing severity of atherosclerosis, described by
some authors. The association seems to be most
pronounced in connectionwith coronary restenosis
following angioplasty or other surgical procedures
for atherosclerotic vessel disease and following
heart transplantation [2–5,8,13]. High levels of
antibodies against CMV seem to be associated
with clinically manifested atherosclerotic disease,
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which may indicate repeated reactivation of latent
infection in many of these patients. On the other
hand, there is relatively little epidemiologic evi-
dence that links CMV infection to classic native
atherosclerosis. Although the total number of
cases included in such studies is sizeable, it is
difﬁcult to draw any deﬁnitive conclusions,
mainly because most of these studies are relatively
small ones, and the clinical target deﬁnitions are
rather heterogeneous. The conclusion of the epi-
demiologic studies is not very convincing, butmay
indicate a relationship, at least in some patient
groups.
The presence of CMV, viral antigen or nucleic
acid in atheromatous and non-atheromatous blood
vessels has been investigated in more than 20
studies. These studies, too, are rather heteroge-
neous. First, the anatomic site of the vessels
includes coronary arteries, aorta, carotid arteries
and others. Second, andmore important, themeth-
ods used to demonstrate the presence of CMV are
varied. They include conventional histology, anti-
gen detection by immunohistochemistry and dot
blot, using different antigens as targets, nucleic
acid detection by dot hybridization, in situ hybri-
dization, and DNA and RNA ampliﬁcation of
different viral gene sequences. It is obvious that
the sensitivity of these methods is markedly dif-
ferent, and therefore the results are not directly
comparable. For example, in one study [14], CMV
genome was detected in 90% of the samples using
DNA ampliﬁcation (PCR), but only in 25% and
29% with antigen detection, using dot blot, direc-
ted against two different CMV antigens. The total
picture is not very convincing [15]. In about 20
studies, making use of all methods, the differences
between diseased and normal vessels are rather
small (47% versus 39%). On the other hand, the
differences are more pronounced in most studies
when using the most sensitive method, genome
ampliﬁcation [14,15]. However, negative ﬁndings
have also been reported [16]. The absence of viable
virus or viral antigen does not necessarily argue
against the possible role of CMV in the develop-
ment of the lesions. The infectious agents may
have been present and initiated the lesion at an
earlier stage. During the subsequent period, the
virus may remain latent, among other cells in the
endothelial cells, and undetectable when studied
with the less sensitive methods, while the few
copies of the genome can be detected with the
very sensitive ampliﬁcation methods.
Following the original observation on the role of
Marek disease herpesvirus (MDV) in development
of atherosclerosis in chicken several animal mod-
els, ﬁrst of all mice and rats, have been used for
studies of the possible role of virus in the patho-
genesis of atherosclerosis. Fabricant and cowor-
kers, in a series of publications beginning in 1971
[17], presented signiﬁcant evidence showing that
infection with MDV speciﬁcally induced athero-
sclerosis in normocholesterolemic chickens. MDV
infects endothelial cells and smooth muscle cells,
and the viral genome was found in cells that made
up the arterial plaques. One important mechanism
seems to be the alteration of arterial smooth mus-
cle cell lipid metabolism, which leads to accumu-
lation of cholesterol and cholesterol esters.
Immunization of chickens with two different vac-
cines prevented the development of MDV-
induced atherosclerotic lesions. BALB/c mice
inoculated intraperitoneally with murine CMV
expressed viral antigens in smooth muscle and
endothelial cells of the aortic wall [18]. This was
accompanied by accumulation of inﬂammatory
cells, similar to that seen in early atherosclerotic
lesions, whether or not the mice were fed a high-
cholesterol diet. Immunosuppression and a high-
cholesterol diet enhanced both viral antigen
expression and the size of early atherosclerotic
lesions in the intima. Simultaneously, the virus
infection was followed by an increased percentage
of low-density lipoprotein cholesterol (LDL-C) in
the serum, the major contributor to atherosclerotic
plaques. These results suggested that in the mouse
model CMV infection is involved in two mechan-
isms that lead to the development of atherosclero-
sis, chronic inﬂammation with immune injury and
an increased proportion of serum LDL-C. Brugge-
mann and coworkers have, in a series of studies,
investigated the etiologic role of rat CMV in the
pathogenesis of vascular disease in rats [19–23].
Infection of immunocompetent rats did not
result in acute clinically apparent infection, but
rather in endothelial damage, increased adhesion
of leukocytes to the aortic intima, and accumu-
lation of lipophages and lipids in the endothelium.
These changes were similar to those seen in non-
infected hypercholesterolemic rats. After balloon
injury in immunosuppressed rats, massive CMV
infection of the neointimal smooth muscle cells
could be observed, followed by the development of
atherosclerotic lesions. The susceptibility and be-
havior of the smooth muscle cells are likely to be
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crucial factors. The same group reported that in
experimental organ transplantation of immuno-
suppressed rats, CMV infection produced suben-
dothelial inﬂammation, endothelial activation,
adhesion of leukocytes to the endothelium and
increased intimal thickening, in spite of only mod-
erate active CMV replication. They suggested that
the transplantation vasculopathy differs from clas-
sic atherosclerosis, and also that the role of virus
infection is different. In transplantation vasculo-
pathy, the virus effect seems to be more an upre-
gulation of immune response to alloantigens and
less of a direct effect. The infection also produced
increased expression of inducible adhesion mole-
cules ICAM-1 and VCAM-1 and their ligands,
leukocyte function antigen-1 (LFA-1) and very late
antigen-4 (VLA-4). Vascular adhesion protein-1
(VAP-1), a transmembrane protein that mediates
lymphocyte binding, was upregulated during
experimental liver allograft rejection, and this
upregulation was prolonged by infection with
rat CMV. An interesting observation was that
CMV infection-enhanced cardiac allograft vascu-
lopathy was abolished by ganciclovir prophylaxis
in the rat. Another group [24] also found that the
neointimal response to injury was signiﬁcantly
greater in CMV-infected rats than in control
animals.
There is a large body of information available on
the interaction of CMV with cells relevant to the
pathogenesis of atherosclerosis. The most impor-
tant cells are certainly the smooth muscle cells and
endothelial cells. Information from such studies
may throw some light on the possible mechanisms
that can be involved. Human CMV (HCMV) can
infect both endothelial cells, smooth muscle cells
and cells in deeper layers of vessels, both in vivo
and in in vitro cell-culture systems. Susceptibility
of endothelial cells to HCMV obtained from dif-
ferent organs and from different types of vessels is
rather varied. According to the cell type and the
experimental conditions, HCMV can produce
either lytic infection or establish latency. Repro-
duction of the virus can be highly active or quite
modest. Actually, endothelial cells may represent
one of the major sites of latency of HCMV in the
organism. HCMV infection of smooth muscle cells
generates reactive oxygen species (ROS) and acti-
vates NF-kB. CMV induction of ROS is at least
partially mediated through a cyclooxygenase-2
(COX-2)-dependent pathway. CMV IE72 and
IE84 gene products have the capacity to transacti-
vate the COX-2 promoter. The cyclooxygenase
inhibitors aspirin and indomethacin reduce the
CMV-induced ROS activation and reduce the
CMV-induced NF-kB activation [25]. NF-kB acti-
vation may result in increased synthesis of various
proteins, including proinﬂammatory cytokines,
chemokines and inducible enzymes. It also
induces enhanced expression of several surface
molecules and factors that are involved in the
adhesion of leukocytes to the endothelial cells, like
ICAM-1, VCAM-1, VAP-1, E-selectin and also
major histocompatibility complex class I antigens
[22,23,26,27]. Increased adhesion of monocytes/
macrophages and other leukocytes is an important
early step in the development of the inﬂammatory
process that eventually leads to atherosclerosis.
According to the response-to-injury hypothesis
of atherosclerosis pathogenesis, the inﬂammatory
process followed by the ﬁbroproliferative
response begins as a protective mechanism which,
with time and subsequent insults, can become
extensive. With time, the excess of inﬂammation
and ﬁbrous connective tissue proliferation,
together with the inﬂow of lipid-containing cells,
become in themselves the disease process. HCMV
can also infect human arterial smooth muscle cells.
In the presence of chemokines, like RANTES and
MCP-1, the infection induces migration of these
cells towards production sites of the chemokines.
The increased migration is also promoted by
expression of the viral chemokine receptor,
US28. The CMV-induced smooth muscle cell
migration is negated by inhibition of late gene
expression. The US28-mediated effect was
observed in CMV-infected smooth muscle cells
obtained from arteries but not in ﬁbroblasts,
endothelial cells and venous smooth muscle cells.
Thismechanism gives one plausible explanation of
the molecular basis that links HCMV infection to
acceleration of vascular disease [28]. It has also
been reported that the immediate early gene pro-
ducts of HCMV increase vascular smooth muscle
cell proliferation, augment migration of these cells
towards the PGDF-b receptor, and, in addition,
enhance the expression of the PGDF-b receptor in a
time-dependent manner [29]. Furthermore, the
same group [30] also reported that an immediate
early gene product of HCMV, IE2-84, may interact
with p53, and by binding to it, inhibit its transcrip-
tional activity. This will lead to inhibition of apop-
tosis, enhanced proliferation and accumulation of
the smooth muscle cells in the neointimal layers.
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Finally, several groups have reported data sup-
porting the hypothesis that several herpesviruses,
including CMV, act as prothrombotic agents by
activation of the coagulation cascade [31–33]. Thus
CMV can induce procoagulant activity on human
endothelial cells, measured by reduction in clot-
ting time. The reason for this is probably that CMV
surface molecules contain a procoagulant phos-
pholipid that promotes the assembly of a func-
tional complex between factor Xa and the cofactor
Va and the ability to form prothrombinase, leading
to thrombin generation.
In conclusion, there is a large amount of data
supporting the hypothesis that CMV can be
involved in the development of atherosclerotic
lesions. Perhaps it is reasonable to say that none
of the many reports by themselves represent very
convincing proof for such a role. It should also be
added that several negative reports have been
published that did not ﬁnd associations between
CMV and vascular disease. But, taken together,
the numerous observations, using different
approaches, arriving at similar or comparable con-
clusions, may indicate that infections should be
included in the array of factors contributing to
atherosclerosis and vascular diseases. Needless
to say, CMV is only one of several infectious agents
that has attracted interest in this ﬁeld. Further
studies are required to clarify this very interesting
and important question.
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